A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer

• ClinicalTrials.gov Identifier: NCT03560479
• Recruitment Status: Recruiting
• First Posted: June 18, 2018
• Last Update Posted: September 12, 2019
• Sponsor: Hamlet Pharma AB
• Information provided by (Responsible Party): Hamlet Pharma AB

Study Description

Brief Summary:

This study evaluates the tolerability and preliminary anti-tumour effect of alpha1H in adults with non-muscle invasive bladder cancer, who are awaiting transurethral surgery.

In the main, blinded part of the study, one group of subjects will receive treatment with alpha1H and the other half will receive placebo. In a second, dose-escalation part of the study, a third and fourth group of subjects will receive increased doses of alpha1H.

The treatment is given on 6 occasions during a period of 22 days. The study duration is 8 - 12 weeks including scheduled follow-up and up to 27 months when an optional 24-months non-interventional follow-up period is included.

Condition or disease	Intervention/treatment	Phase
Non-muscle Invasive Bladder Cancer	Drug: alpha1H, 7.4 mg/mL; Other: placebo; Drug: alpha1H, 37 mg/mL; Drug: alpha1H, 74 mg/mL	Phase 1; Phase 2

Detailed Description:

Protein-lipid complexes represent a new type of tumouricidal biologicals, with broad effects against cancers of different origins. The investigational product alpha1H is a synthetic peptide, corresponding to the alpha1 domain of α-lactalbumin, in complex with oleic acid. Alpha1H is a further development product of HAMLET, a complex between human alpha-lactalbumin and oleic acid, which has shown broad anti-tumor activity with a high degree of selectivity.

This study is a combined phase 1/2, placebo controlled, double blind study in subjects with non-muscle invasive bladder cancer awaiting transurethral resection of bladder (TURB). The first, main part of the study is randomized 1/1 and the subjects will receive intravesical instillation of either alpha1H or placebo on 6 occasions during a period of 22 days (on days 1, 3, 5, 8, 15 and 22). In a second, open, dose-escalation (DE) part of the study, two additional groups will receive increased doses of alpha1H in a standard 3+3 design in order to determine a Maximum Tolerated Dose (MTD) or alternatively, a Maximum Administered Dose (MAD). The same treatment schedule as in part 1 will be followed. One group will receive a dose of 5 times the original dose and, if tolerated, the last group will receive a dose of 10 times the original dose.

Cell shedding is quantified and characterized at each treatment occasion. The bladder tumors are characterized prior treatment and prior to the scheduled surgery. Remaining tumors will be removed by TURB (according to European Association of Urology (EAU) Guidelines recommendations) and tissues will be obtained for analyses.

A follow-up Visit will take place 30 days after the last administration of study treatment.

The total study duration of the main study is 8 - 12 weeks. After the main study, the subjects may continue in an optional extended 24-months follow-up period.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 52 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment

Intervention Model Description

Part 1 (Main part): Patients are randomized to receive intravesical instillations of either alpha1H (7.4 mg/mL) or placebo. The randomization ratio is 1:1.

Part 2 (DE part): In this open part of the study, two groups of patients will receive escalating doses of alpha1H in a standard 3+3 design. One group will receive a dose of 37 mg/mL and, if tolerated, one group will receive a dose of 74 mg/mL.

• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Randomized Placebo Controlled Phase I/II Study Evaluating the Safety and Efficacy of alpha1H in Adult Patients With Non-muscle Invasive Bladder Cancer Awaiting Transurethral Surgery
• Actual Study Start Date: May 21, 2018
• Estimated Primary Completion Date: March 2020
• Estimated Study Completion Date: March 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: alpha1H, 7.4 mg/mL; alpha1H (7.4 mg/mL), solution for instillation, 30 mL	Drug: alpha1H, 7.4 mg/mL; Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
Placebo Comparator: placebo; Placebo, 0.9% NaCl (sodium chloride), 30 mL	Other: placebo; Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
Experimental: alpha1H, 37 mg/mL; alpha1H (37 mg/mL), solution for instillation, 30 mL	Drug: alpha1H, 37 mg/mL; Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
Experimental: alpha1H, 74 mg/mL; alpha1H (74 mg/mL), solution for instillation, 30 mL	Drug: alpha1H, 74 mg/mL; Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)

Outcome Measures

Primary Outcome Measures :

1. Safety as Adverse Events Profile [ Time Frame: From signing of informed consent (Day 1) and until 30 days after the last dose (Day 52). ]
   Incidence of adverse events and classification in terms of severity, causality and outcome
2. Efficacy as Cell Shedding [ Time Frame: Days 1 to 22 ]
   Change in cell shedding into urine (number of epithelial cells per mL of urine).
3. Change from baseline in characteristics of papillary tumors [ Time Frame: Prior to treatment (Baseline) and on Day 30, in connection with scheduled surgery. ]
   The bladder tumors will be characterised by in vivo imaging during examination by cystoscopy.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patient with non-muscle invasive papillary bladder cancer (NMIBC) based on cystoscopy appearance, on the waiting list for TURB.
• Negative pregnancy test in women of childbearing potential.
• Appropriate methods of contraception in women of childbearing potential during study.
• Patients should be able to keep the content of the bladder for at least one hour.

Exclusion Criteria:

• Patient with a previous history of muscle invasive bladder cancer.
• Patient with a history of NMIBC with an interval shorter than 6 months after previous TURB.
• Previous intravesical Bacillus Calmette-Guerin (BCG) immunotherapy in the last 12 months.
• Previous intravesical chemotherapy in the last 12 months.
• Participants with any other cancer diagnosis within the last 5 years (except of skin basaliomas).
• Acute urinary tract infection
• Participants with prior radiotherapy or systemic chemotherapy.
• Participants receiving any other investigational agent or non-marketed product one month prior to Visit 1 and during the trial.
• Any concurrent illness that may render a participant ineligible or limit compliance with study requirements.
• Previously enrolled in this trial.

Contacts and Locations

Contacts

Contact: Catharina Svanborg, Prof.; +4640122505; catharina.svanborg@med.lu.se

Contact: Mats Persson, PhD; +4640122500; mats.persson@hamletpharma.com

Locations

Czechia

Motol University Hospital; Recruiting

Prague, Czechia

Contact: Marek Babjuk, MD, Prof

Sponsors and Collaborators

Hamlet Pharma AB

Investigators

• Principal Investigator: Marek Babjuk, MD, Prof.; Motol University Hospital

More Information

• Responsible Party: Hamlet Pharma AB
• ClinicalTrials.gov Identifier: NCT03560479
• Other Study ID Numbers: HP002-001; 2016-004269-14 ( EudraCT Number )
• First Posted: June 18, 2018
• Last Update Posted: September 12, 2019
• Last Verified: September 2019

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Hamlet Pharma AB:

First-in human; Phase 1; Phase 2; Safety; Tolerability; Cancer; Bladder cancer; Clinical trial; Anti-cancer; Antineoplastic; alpha1H; HAMLET; Urothelial; Malignant; Papillary; Transurethral; Non-muscle invasive; Instillation; Intravesical

Additional relevant MeSH terms:

Urinary Bladder Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Urinary Bladder Diseases; Urologic Diseases